arrow
É

Éric Durot

university hospital of reims
H指数:17
被引数:991

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trial

诱导治疗结束时的循环肿瘤DNA优于常规细胞微小残留病,用于预测滤泡性淋巴瘤的早期进展:RELEVANCE随机试验的辅助研究

2026-09-290
OAAI
LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma

LTB-TREAT:一种用于低肿瘤负荷滤泡性淋巴瘤治疗时间预测的国际验证性预后模型

2026-08-300
OAAI
Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma

原发性纵隔B细胞淋巴瘤中联合基线FDG PET/CT放射组学参数的预后价值

2026-05-140
OAAI
Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study

原发纵隔大B细胞淋巴瘤中循环肿瘤DNA的 interim assessment:一项多中心LYSA研究

2026-04-160
OA
CD3xCD20 bispecific antibodies in transformed Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

CD3xCD20 双特异性抗体在转化型华氏巨球蛋白血症/淋巴浆细胞样淋巴瘤中的应用

2026-03-250
OAAI
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia

POD24是沃尔德斯特伦巨球蛋白血症患者预后的新型决定因素。

2026-01-090
OAAI
Large B-cell Lymphoma: The LYSA pragmatic guidelines

弥漫大B细胞淋巴瘤:LYSA实用性指南

2025-12-030
OAAI
Waldenström’s macroglobulinemia: the LYSA pragmatic guidelines

华氏巨球蛋白血症:LYSA实用指南

2025-11-280
PRE
Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study

Brisou, G.; Paillassa, J.; Bernard, S.; Tournilhac, O.; Fornecker, L.M.; Maloisel, F.; Gastaud, L.; Durot, E.; Tempescul, A.; Braun, T.; 等. 塔法西单抗联合来那度胺在复发或难治性弥漫大B细胞淋巴瘤中的临床获益:EarlyMIND研究真实世界数据. Haematologica 2025, 110, 2400–2412. [Google Scholar] [CrossRef]

2025-10-010
OAAI
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell Lymphoma

身体成分对原发性纵隔大B细胞淋巴瘤患者治疗毒性和预后的影响

2025-07-110
OAAI
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease

第十二届华氏巨球蛋白血症国际研讨会第三共识小组关于高风险疾病患者管理的报告

2025-04-080
PRE
Report of Consensus Panel 6 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on Diagnosis and Management of Transformed Waldenstrom's Macroglobulinemia

第十二届华氏巨球蛋白血症国际研讨会第六共识专家组关于转化型华氏巨球蛋白血症的诊断与管理的报告

2025-04-080
PRE
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network
LEUKEMIA
IF13.4
2024-04-272
OAAI
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma
2023-12-042
OAAI
Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse
2023-11-302
OA
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
2023-09-274
OAAI